Lab
Lab24, LLC
Lab24, LLC was paid $11.51M by Medicaid between Jan 2020 and Dec 2024, across 54 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 71% of everything it billed.
33Billing provider infoLAB24, LLC
REDDING, CA 96002
REDDING, CA 96002
33aNPI1275018871assigned 09/28/2018
33bProvider typeClinical Medical Laboratory
28Total paid$11.51M
24GClaims105,295
24DCodes billed54
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#63 of 561
Median peer was paid$222K
This provider vs. median52×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SERLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,771 | $490K | |
| 2021 | 32,331 | $2.62M | |
| 2022 | 29,799 | $2.64M | |
| 2023 | 17,044 | $2.42M | |
| 2024incomplete | 21,350 | $3.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 71% | 51,155 | 32,442 | $8.21M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 15% | 27,059 | 18,217 | $1.77M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.1% | 3,536 | 3,228 | $355K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.9% | 1,474 | 1,427 | $337K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.8% | 7,272 | 7,121 | $327K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 429 | 423 | $139K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,046 | 422 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 966 | 947 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 939 | 918 | $26K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 860 | 842 | $24K |
| 87511 | <1% | 763 | 743 | $22K | |
| 87640 | <1% | 659 | 652 | $17K |
42 more codes
| 87150 | <1% | 98 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 950 | $14K |
| 87481 | <1% | 439 | $13K | |
| 87529 | <1% | 261 | $12K | |
| 87541 | <1% | 407 | $11K | |
| 87498 | <1% | 407 | $11K | |
| 87581 | <1% | 407 | $11K | |
| 87486 | <1% | 407 | $11K | |
| 87653 | <1% | 333 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 68 | $8K |
| 87641 | <1% | 256 | $8K | |
| 86780 | <1% | 502 | $5K | |
| 86696 | <1% | 346 | $5K | |
| 80053 | Comprehensive metabolic panel | <1% | 597 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 335 | $5K |
| 87799 | <1% | 27 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 178 | $4K |
| 87510 | <1% | 234 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 601 | $4K |
| 86695 | <1% | 358 | $4K | |
| 80061 | Lipid panel | <1% | 295 | $3K |
| 87563 | <1% | 123 | $3K | |
| 81514 | <1% | 12 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 51 | $2K |
| 87335 | <1% | 205 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 245 | $2K |
| 87274 | <1% | 178 | $2K | |
| 87273 | <1% | 178 | $2K | |
| 80299 | <1% | 130 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 41 | $1K |
| 87660 | <1% | 52 | $895.45 | |
| 87109 | <1% | 63 | $837.52 | |
| 82746 | <1% | 61 | $784.20 | |
| 82607 | <1% | 50 | $613.18 | |
| 83540 | <1% | 75 | $409.32 | |
| 82728 | <1% | 28 | $301.75 | |
| 84439 | <1% | 35 | $276.85 | |
| 87520 | <1% | 12 | $261.96 | |
| 83550 | <1% | 39 | $248.04 | |
| 82747 | <1% | 23 | $229.80 | |
| 80178 | <1% | 16 | $94.08 | |
| 83735 | <1% | 14 | $77.48 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSERLE, JOHN (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Lincoln County Public Hospital District 1 | Odessa, WA | $603K |
| Our Lady of Lourdes Health Center | Pasco, WA | $316K |
| Lincoln County Public Hospital District 1 | Odessa, WA | $258K |
| Our Lady of Lourdes Health Center | Pasco, WA | $226K |
| Our Lady of Lourdes Health Center Dba Lourdes Ear Nose and Throat Asso | Pasco, WA | $36K |
| Our Lady of Lourdes Health Center | Pasco, WA | $29K |
| Our Lady of Lourdes Health Center | Pasco, WA | $8K |
| Our Lady of Lourdes Health Center | Pasco, WA | $3K |
| Our Lady of Lourdes Hospital at Pasco | Pasco, WA | $2K |
| Lincoln County Public Hospital District 1 | Odessa, WA | $0.00 |
| Our Lady of Lourdes Health Center | Richland, WA | $0.00 |
| Our Lady of Lourdes Hosptial at Pasco | Pasco, WA | $0.00 |
| Our Lady of Lourdes Hosptial at Pasco | Kennewick, WA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.